Terran Biosciences
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Florida, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Miami, Florida, United StatesWebsite
www.terranbiosciences.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Terran Biosciences
Terran Biosciences is a biotech platform company devoted to the development of transformative therapeutics and technologies for patients with neurological and psychiatric diseases. The company's portfolio includes a late-stage therapy for schizophrenia, late-stage selective serotonin 2A receptor antagonists, a drug design engine that has enabled first-in-class and best-in-class psychedelic therapies, and an AI-enabled imaging software platform. The company's team consists of biopharma industry professionals and successful physician-entrepreneurs, and the company is uniquely positioned to become a leader in the rapidly growing renaissance in neuroscience.Explore more
Terran Biosciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Terran Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Terran Biosciences launches new products
Earning: See what the market has to say on Terran Biosciences recently announced quarterly report
Terran Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Terran Biosciences has new funding data
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Terran Biosciences
Check if Terran Biosciences has recently received funding, and reach out quickly before it becomes old news!
Check out if Terran Biosciences is spiking on competitors!
Click to see if Terran Biosciences had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Terran Biosciences
Find 2 more new buyers
Compare Similar Companies to Terran Biosciences
Compare insights from companies similar to Terran Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Terran Biosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Terran Biosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Terran Biosciences.
Terran Biosciences financials insights
Gather financial insights about Terran Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Angel/Seed
$9M
Terran Biosciences Tech Stack
A closer look at the technologies used by Terran Biosciences
Most Recent Scoops
Person-Based
Funding
Funding
Project
Product Development, Intellectual Property, Legal Affairs
Project
Product Management, Compliance, Legal Affairs, Software
Left Company
Executive Move
Terran Biosciences News & Media
Terran Biosciences Granted US Patent for the World’s First New Forms of MDMA, Potentially Clearing the Path to a Future 505(b)(2) Approval
MIAMI--(BUSINESS WIRE)--Terran Biosciences granted a patent for new salts & polymorphs of MDMA; the world's only granted composition of matter patent on a new form of MDMA.Terran Biosciences Receives FDA Clearance for NM-101, the industry’s first software for the analysis of neuromelanin-sensitive MRI
MIAMI--(BUSINESS WIRE)--Terran Biosciences, Inc. ("Terran"), a biotech platform company developing therapeutics and technologies for patients with neuropsychiatric illnesses, has received FDA clearance to market NM-101, a cloud-based software platform to analyze neuromelanin-sensitive MRI scans. Currently, there is no other FDA-cleared software indicated for the analysis of neuromelanin MRI on the market, making Terran’s technology the world’s first. NM-101 is a cloud-based analysis platform thTerran Biosciences Receives Notice of Allowance for Four US Patents Including for the World’s First New Salts and Polymorphs of Psilocybin, potentially enabling future 505(b)(2) pathway
MIAMI--(BUSINESS WIRE)--Terran Biosciences, Inc. ("Terran"), a biotech platform company developing therapeutics and technologies for patients with neuropsychiatric illnesses, has received notice of allowance from the United States Patent and Trademark Office (USPTO) for four US patents covering a number of breakthroughs in the psychedelic therapeutic space. Two of these patents cover the world’s first new forms of psilocybin (psilocybin HCl and psilocybin edisylate) and their method of use in tTerran Biosciences CEO to Deliver Keynote Speech at Microdose's 3rd Annual Wonderland Conference
New York, New York--(Newsfile Corp. - November 2, 2023) - Terran Biosciences, a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, today announced that Terran's founder and CEO, Sam Clark, MD, PhD, will be delivering a keynote address at Microdose's 3rd Annual Wonderland Conference in Miami, Florida, November 9th. In his talk entitled "Longevity and the Aging Brain: A Novel Psychedelic-based Therapeutic for...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Terran Biosciences
Sign Up For FreeTo access detailed company insights
Terran Biosciences is a biotech platform company devoted to the development of transformative therapeutics and technologies for patients with neurological and psychiatric diseases. The company's portfolio includes a late-stage therapy for schizophrenia, late-stage selective serotonin 2A receptor antagonists, a drug design engine that has enabled fi... Read More
